Base triplet nonisomorphism strongly influences DNA triplex conformation: Effect of nonisomorphic G∗︁ GC and A∗︁ AT triplets and bending of DNA triplexes

Biopolymers ◽  
2006 ◽  
Vol 82 (5) ◽  
pp. 443-461 ◽  
Author(s):  
T. Rathinavelan ◽  
N. Yathindra
Keyword(s):  
2018 ◽  
Vol 20 (20) ◽  
pp. 14013-14023 ◽  
Author(s):  
Belinda J. Boehm ◽  
Charles Whidborne ◽  
Alexander L. Button ◽  
Tara L. Pukala ◽  
David M. Huang

Molecular dynamics simulations are used to elucidate the structure and thermodynamics of DNA triplexes associated with the neurodegenerative disease Friedreich's ataxia (FRDA), as well as complexes of these triplexes with the small molecule netropsin, which is known to destabilise triplexes.


2019 ◽  
Vol 7 (5) ◽  
pp. 763-767 ◽  
Author(s):  
Yao Qin ◽  
Daxiu Li ◽  
Ruo Yuan ◽  
Yun Xiang

A new silver ion-stabilized DNA triplex enables enzyme-free and amplified sensitive fluorescence detection of transcription factors.


2020 ◽  
Vol 20 (16) ◽  
pp. 1943-1955
Author(s):  
Neelam Lohani ◽  
Moganty R. Rajeswari

Background: The high mobility group box 1 (hmgb1) is one of the frequently over-expressed genes whose aberrant expression is reported in a number of human cancers. Various strategies are underway to inhibit hmgb1 expression in cancer cells having considerable therapeutic value. Objective: The present work involves selective transcriptional inhibition of the hmgb1 gene using selective DNA triplex structure-based gene technology. Here, the promoter region of the hmgb1 gene at position (-183 to -165) from the transcription start site as a target was selected using bioinformatic tools. Methods: The DNA triplex formation by the DNA of the target gene and TFO was confirmed using UV absorption spectroscopy, Circular Dichroism, and Isothermal Calorimetry. Results: Treatment of HepG2 cell with specific Triplex-forming Oligonucleotide significantly downregulated HMGB1 expression level at mRNA and protein levels by 50%, while the classical anticancer drugs, actinomycin/ adriamycin as positive controls showed 65% and the combination of TFO and drug decreased by 70%. The anti-proliferative effects of TFO correlated well with the fact of accumulation of cells in the Go phase and apoptotic cell death. Further, the binding of anti-cancer drugs to hmgb1 is stronger in DNA triplex state as compared to hmgb1 alone, suggesting the combination therapy as a better option. Conclusion: Therefore, the ability of hmgb1 targeted triplex-forming oligonucleotide in combination with triplex selective anticancer drug holds promise in the treatment of malignancies associated with hmgb1 overexpression. The result obtained may open up new vistas to provide a basis for the rational drug design and searching for high-affinity ligands with a high triplex selectivity.


2003 ◽  
Vol 107 (1) ◽  
pp. 323-330 ◽  
Author(s):  
Martin Peters ◽  
Isabel Rozas ◽  
Ibon Alkorta ◽  
Jose Elguero
Keyword(s):  

2009 ◽  
Vol 53 (1) ◽  
pp. 163-164
Author(s):  
T. Kanamori ◽  
H. Tsunoda ◽  
A. Ohkubo ◽  
M. Sekine ◽  
K. Seio
Keyword(s):  

Biochemistry ◽  
1994 ◽  
Vol 33 (14) ◽  
pp. 4111-4120 ◽  
Author(s):  
Karen Dittrich ◽  
Juan Gu ◽  
Robert Tinder ◽  
Michael Hogan ◽  
Xiaolian Gao

ChemInform ◽  
2001 ◽  
Vol 32 (5) ◽  
pp. no-no
Author(s):  
Pascal Savy ◽  
Rachid Benhida ◽  
Jean-Louis Fourrey ◽  
Rosalie Maurisse ◽  
Jian-Sheng Sun

Sign in / Sign up

Export Citation Format

Share Document